These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 28116786)

  • 1. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
    Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
    Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Messinger YH; Gaynon PS; Sposto R; van der Giessen J; Eckroth E; Malvar J; Bostrom BC;
    Blood; 2012 Jul; 120(2):285-90. PubMed ID: 22653976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
    Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
    Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
    Keino D; Ohyama R; Ashikaga T; Morimoto M; Yamashita A; Kondoh K; Kinoshita A
    Rinsho Ketsueki; 2014 Mar; 55(3):327-33. PubMed ID: 24681936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
    Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
    Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
    Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
    Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Nachmias B; Shaulov A; Gatt ME; Shapira M; Gural A
    Acta Haematol; 2018; 140(4):209-214. PubMed ID: 30343286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
    Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
    Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
    J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
    Horton TM; Whitlock JA; Lu X; O'Brien MM; Borowitz MJ; Devidas M; Raetz EA; Brown PA; Carroll WL; Hunger SP
    Br J Haematol; 2019 Jul; 186(2):274-285. PubMed ID: 30957229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.